End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
50.92 CNY | +1.03% | +1.84% | +25.11% |
Oct. 31 | Dong-E-E-Jiao's Nine-Moth Profit Rises on Higher Revenue | MT |
Oct. 30 | Dong-E-E-Jiao Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
Sales 2023 * | 4,760 M 667 M | Sales 2024 * | 5,566 M 780 M | Capitalization | 32.79 B 4,594 M |
---|---|---|---|---|---|
Net income 2023 * | 1,051 M 147 M | Net income 2024 * | 1,278 M 179 M | EV / Sales 2023 * | 5,85x |
Net cash position 2023 * | 4,963 M 695 M | Net cash position 2024 * | 5,095 M 714 M | EV / Sales 2024 * | 4,98x |
P/E ratio 2023 * | 31,3x | P/E ratio 2024 * | 25,8x | Employees | 3,703 |
Yield 2023 * | 2,40% | Yield 2024 * | 2,85% | Free-Float | 66.22% |
More Fundamentals
* Assessed data
More news
1 day | +1.03% | ||
1 week | +1.84% | ||
Current month | +1.03% | ||
1 month | +8.80% | ||
3 months | +1.45% | ||
6 months | +1.64% | ||
Current year | +25.11% |
1 week
49.40
51.50

1 month
46.08
51.50

Current year
39.17
55.68

1 year
37.59
55.68

3 years
27.60
55.68

5 years
24.92
55.68

10 years
24.92
73.71

Members of the board | Title | Age | Since |
---|---|---|---|
Guang Li Liu
BRD | Director/Board Member | 59 | 2008 |
Guang Wei Wen
BRD | Director/Board Member | 60 | 2021 |
Jing Wen Weng
BRD | Director/Board Member | 47 | 2019 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.66% | 63 M€ | -12.61% | ||
0.48% | 2 M€ | -12.57% | - | |
0.47% | 9 M€ | -11.36% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-01 | 50.92 | +1.03% | 3,520,116 |
23-11-30 | 50.40 | +0.04% | 3,435,746 |
23-11-29 | 50.38 | -0.18% | 2,500,440 |
23-11-28 | 50.47 | +0.58% | 3,785,445 |
23-11-27 | 50.18 | +0.36% | 4,004,255 |
End-of-day quote Shenzhen Stock Exchange, December 30, 2023
More quotes
Dong-E-E-Jiao Co., Ltd. specializes in the manufacturing and marketing of Chinese traditional medicines and health products. The products are primarily for deficiencies in the blood, immunodeficiency, indigestion, insomnia and fatigue.
Sector
Pharmaceuticals
Calendar
2024-03-14
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
BUY
Number of Analysts
13
Last Close Price
50.92CNY
Average target price
57.05CNY
Spread / Average Target
+12.04%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.11% | 4 594 M $ | |
-16.96% | 5 823 M $ | |
+82.30% | 3 269 M $ | |
+42.10% | 3 200 M $ | |
-15.14% | 2 763 M $ | |
+13.01% | 2 156 M $ | |
-20.42% | 1 902 M $ | |
+4.60% | 1 767 M $ | |
+1.23% | 1 603 M $ | |
+31.37% | 1 353 M $ |